Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Date:3/11/2009

mber of ADSs outstanding 21,510,851 21,510,851 21,512,351 21,512,351

Notes to reconciliation of our GAAP statements of income to our adjusted non-GAAP statements of income:

    (1) To exclude share-based compensation expense.
    (2) To exclude one-time upfront payment for licenses fee of RMB 6,948,000
        and share-based compensation expense of RMB 162,000 for R&D staff.
    (3) To exclude investment losses on available-for-sale securities
    (4) No income tax effect on adjustments is required as they are incurred
        by overseas companies that are not subject to income tax.




    Three Months Ended December 31, 2007
    (unaudited)        Actual   Actual  Adjustment    Adjusted       Adjusted
                        GAAP     GAAP                 Non-GAAP       Non-GAAP
                         RMB      US$     RMB           RMB             US$
    Net Revenues:
     EPIAO             29,798    4,085                 29,798          4,085
     TPIAO             11,718    1,606                 11,718          1,606
     Intefen            1,128      155                  1,128            155
     Inleusin             251       34                    251             34
     Iron                 970      133                    970            133
     Export             1,625      223                  1,625            223
     Others               193       26                    193             26

    Total revenues     45,683    6,262                 45,683          6,262
    Cost of revenues   (5,737)    (786)                (5,737)          (786)

    Gross profit       39,946    5,476                 39,946          5,476

    Operating expenses
    Research and
     Development costs (3,715)    (509)                (3,715)          (509)
    Sales, marketing
     and distribution
     expenses         (22,712)  (3,114)               (22,712)        (3,114)
'/>"/>
SOURCE 3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
2. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
3. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
4. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
5. 3SBio Inc. Announces Third Quarter 2008 Results
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
9. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
10. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
11. 3SBio Inc. Announces Results of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3